Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase 2 Study to Evaluate Three Treatment Regimens of SHAPE, a Histone Deacetylase Inhibitor, in Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma

Next Previous
Search
Trial Profile

A Randomized Phase 2 Study to Evaluate Three Treatment Regimens of SHAPE, a Histone Deacetylase Inhibitor, in Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Remetinostat (Primary)
  • Indications Cutaneous T-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors TetraLogic Pharmaceuticals

    • Most Recent Events

    • 25 Jul 2018 According to a Medivir AB media release, data were presented at the International Investigative Dermatology (IID) meeting
    • 18 May 2018 According to a Medivir AB media release, data from this study will be presented at the International Investigative Dermatology (IID) meeting on 19th May 2018.
    • 13 Oct 2017 According to a Medivir AB media release, data were presented as an abstract at the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force meeting October 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top